Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective cut by stock analysts at Cantor Fitzgerald from $16.00 to $9.00 in a research note issued on Wednesday, The Fly reports. The firm currently has a “neutral” rating on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 4.53% from the stock’s previous close.
Other analysts have also issued reports about the stock. Citigroup cut their target price on shares of Teva Pharmaceutical Industries from $27.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, April 11th. UBS Group started coverage on shares of Teva Pharmaceutical Industries in a research note on Thursday, March 7th. They set a “buy” rating and a $22.00 target price for the company. Morgan Stanley lowered shares of Teva Pharmaceutical Industries from an “overweight” rating to an “equal weight” rating and set a $17.00 target price for the company. in a research note on Wednesday, March 6th. Zacks Investment Research raised shares of Teva Pharmaceutical Industries from a “strong sell” rating to a “hold” rating in a research note on Wednesday, March 20th. Finally, SunTrust Banks started coverage on shares of Teva Pharmaceutical Industries in a research note on Tuesday, March 19th. They set a “hold” rating and a $17.00 target price for the company. Five analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $17.05.
TEVA stock traded down $0.10 on Wednesday, hitting $8.61. 15,636,077 shares of the company’s stock traded hands, compared to its average volume of 13,228,337. Teva Pharmaceutical Industries has a 1-year low of $8.25 and a 1-year high of $25.96. The firm has a market cap of $8.86 billion, a PE ratio of 3.08, a P/E/G ratio of 1.09 and a beta of 1.64. The company has a debt-to-equity ratio of 1.66, a current ratio of 0.96 and a quick ratio of 0.62.
In other Teva Pharmaceutical Industries news, VP Notaristefani Carlo De sold 16,070 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $11.42, for a total value of $183,519.40. Following the transaction, the vice president now owns 49,659 shares in the company, valued at approximately $567,105.78. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Sol J. Barer acquired 111,000 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was bought at an average price of $8.98 per share, for a total transaction of $996,780.00. Following the purchase, the director now owns 115,942 shares in the company, valued at approximately $1,041,159.16. The disclosure for this purchase can be found here. Insiders have sold 18,860 shares of company stock worth $226,854 in the last 90 days. 0.49% of the stock is owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the business. Kore Private Wealth LLC acquired a new position in Teva Pharmaceutical Industries in the 1st quarter valued at approximately $29,000. Bruderman Asset Management LLC increased its stake in Teva Pharmaceutical Industries by 2,175.0% in the 4th quarter. Bruderman Asset Management LLC now owns 2,366 shares of the company’s stock valued at $36,000 after buying an additional 2,262 shares during the period. Coastal Investment Advisors Inc. acquired a new position in Teva Pharmaceutical Industries in the 1st quarter valued at approximately $37,000. Lindbrook Capital LLC increased its stake in Teva Pharmaceutical Industries by 61.2% in the 1st quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock valued at $39,000 after buying an additional 945 shares during the period. Finally, Cullen Frost Bankers Inc. acquired a new position in Teva Pharmaceutical Industries in the 1st quarter valued at approximately $40,000. Hedge funds and other institutional investors own 65.10% of the company’s stock.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Recommended Story: What is an SEC Filing?
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.